Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

The medical treatment of depression, 1991-1996: productive inefficiency, expected outcome variations, and price indexes.

Berndt ER, Bir A, Busch SH, Frank RG, Normand SL.

J Health Econ. 2002 May;21(3):373-96.

PMID:
12022264
2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
3.

The impact of treatment-resistant depression on health care utilization and costs.

Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, Russell JM.

J Clin Psychiatry. 2002 Nov;63(11):963-71.

PMID:
12444808
4.

Cost of depression in Europe.

Sobocki P, Jönsson B, Angst J, Rehnberg C.

J Ment Health Policy Econ. 2006 Jun;9(2):87-98.

PMID:
17007486
5.

Recovery from depression predicts lower health services costs.

Simon GE, Khandker RK, Ichikawa L, Operskalski BH.

J Clin Psychiatry. 2006 Aug;67(8):1226-31.

PMID:
16965200
6.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
7.

Organizational and client determinants of cost in outpatient substance abuse treatment.

Beaston-Blaakman A, Shepard D, Horgan C, Ritter G.

J Ment Health Policy Econ. 2007 Mar;10(1):3-13.

PMID:
17417043
8.
9.

Cost-effectiveness of improving primary care treatment of late-life depression.

Katon WJ, Schoenbaum M, Fan MY, Callahan CM, Williams J Jr, Hunkeler E, Harpole L, Zhou XH, Langston C, Unützer J.

Arch Gen Psychiatry. 2005 Dec;62(12):1313-20.

PMID:
16330719
10.

Cost-effectiveness of cognitive-behavioural therapy and drug interventions for major depression.

Vos T, Corry J, Haby MM, Carter R, Andrews G.

Aust N Z J Psychiatry. 2005 Aug;39(8):683-92.

PMID:
16050922
11.

Determinants of direct cost differences among US employees with major depressive disorders using antidepressants.

Birnbaum HG, Ben-Hamadi R, Greenberg PE, Hsieh M, Tang J, Reygrobellet C.

Pharmacoeconomics. 2009;27(6):507-17. doi: 10.2165/00019053-200927060-00006.

PMID:
19640013
12.

Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.

Insinga RP, Itzler RF, Pellissier JM.

Pharmacoeconomics. 2007;25(2):155-69.

PMID:
17249857
13.

Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women.

Revicki DA, Siddique J, Frank L, Chung JY, Green BL, Krupnick J, Prasad M, Miranda J.

Arch Gen Psychiatry. 2005 Aug;62(8):868-75.

PMID:
16061764
14.

Changing mix of medical care services: stylized facts and implications for price indexes.

Aizcorbe A, Nestoriak N.

J Health Econ. 2011 May;30(3):568-74. doi: 10.1016/j.jhealeco.2011.04.002. Epub 2011 Apr 21. Erratum in: J Health Econ. 2011 Jul;30(4):842.

PMID:
21621288
15.

The cost of treating anxiety: the medical and demographic correlates that impact total medical costs.

Marciniak MD, Lage MJ, Dunayevich E, Russell JM, Bowman L, Landbloom RP, Levine LR.

Depress Anxiety. 2005;21(4):178-84.

PMID:
16075454
16.

Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder.

van Baardewijk M, Vis PM, Einarson TR.

Curr Med Res Opin. 2005 Aug;21(8):1271-9.

PMID:
16083537
17.

The economic burden of lung cancer and the associated costs of treatment failure in the United States.

Kutikova L, Bowman L, Chang S, Long SR, Obasaju C, Crown WH.

Lung Cancer. 2005 Nov;50(2):143-54. Epub 2005 Aug 19.

PMID:
16112249
18.

Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders.

Issakidis C, Sanderson K, Corry J, Andrews G, Lapsley H.

Psychol Med. 2004 Jan;34(1):19-35.

PMID:
14971624
19.

Patient preferences for depression treatment programs and willingness to pay for treatment.

Morey E, Thacher JA, Craighead WE.

J Ment Health Policy Econ. 2007 Jun;10(2):73-85.

PMID:
17603148
20.

Prevalence and costs of major depression among elderly claimants with diabetes.

Finkelstein EA, Bray JW, Chen H, Larson MJ, Miller K, Tompkins C, Keme A, Manderscheid R.

Diabetes Care. 2003 Feb;26(2):415-20.

PMID:
12547872
Items per page

Supplemental Content

Write to the Help Desk